Researchers from Bioland Laboratory (Guangzhou Regenerative Medicine and Health - Guangdong Laboratory) and the University of Groningen have generated a series of novel biphenyl-benzamides as inhibitors of cell division protein FtsZ with encouraging antibacterial activity.

Metabrain Research and Shanghai Visonpharma have presented macrocyclic Toll-like receptor 7 (TLR7) agonists reported to be useful for the treatment of hepatitis B virus (HBV), HCV, HIV and influenza virus infections, and cancer.

Scientists from the University Grenoble Alpes in France and colleagues have recently identified a promising drug candidate with broad-spectrum activity against apicomplexans using a drug repurposing strategy.

Aridis Pharmaceuticals announced preclinical data for its inhaled monoclonal antibody (MAb) cocktail, AR-701.

Vellore Institute of Technology University (VIT) and BG Negev Technologies and Applications have described new curcumin or piperine analogues acting as NF-kappaB (NFKB) activation inhibitors and/or quorum sensing signaling inhibitors reported to be useful for treatment of cancer, fungal and bacterial infections and inflammatory disorders.

Tetra Bio-Pharma has announced new promising preclinical results with ARDS-003 (onternabez) from live SARS-CoV-2 virus infection studies, as well as a septic lung model, carried out by independent researchers.

Shionogi has reported that S-217622 (ensitrelvir fumaric acid), the company's orally administered antiviral drug for COVID-19, shows high in vitro antiviral activity against the SARS-CoV-2 Omicron subvariant BA.2.75.

NanoViricides has outlined plans to develop NV-387-T for monkeypox virus. NV-387-T is made by encapsulating tecovirimat within NV-387 polymeric micelles.

HDT Bio has been awarded a nearly USD 1.8 million grant from the U.S. Army Medical Research Acquisition Activity to develop HDT-201 into an antiviral intranasal spray that can stimulate the body's innate immune system to treat and prevent a broad spectrum of deadly human viruses.

SymBio Pharmaceuticals has entered into a collaboration agreement with the National Institute of Neurological Disorders and Stroke (NINDS) on the evaluation of brincidofovir's potential antiviral effect on Epstein Barr virus (EBV).